• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

造血作用和血液学药物毒性中的溶质载体核苷转运体:一种观点

Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective.

作者信息

Ali Syed Saqib, Raj Ruchika, Kaur Tejinder, Weadick Brenna, Nayak Debasis, No Minnsung, Protos Jane, Odom Hannah, Desai Kajal, Persaud Avinash K, Wang Joanne, Govindarajan Rajgopal

机构信息

Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.

Department of Pharmaceutics, College of Pharmacy, University of Washington, Seattle, WA 98195, USA.

出版信息

Cancers (Basel). 2022 Jun 25;14(13):3113. doi: 10.3390/cancers14133113.

DOI:10.3390/cancers14133113
PMID:35804885
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9264962/
Abstract

Anticancer nucleoside analogs produce adverse, and at times, dose-limiting hematological toxicities that can compromise treatment efficacy, yet the mechanisms of such toxicities are poorly understood. Recently, cellular nucleoside transport has been implicated in normal blood cell formation with studies from nucleoside transporter-deficient mice providing additional insights into the regulation of mammalian hematopoiesis. Furthermore, several idiopathic human genetic disorders have revealed nucleoside transport as an important component of mammalian hematopoiesis because mutations in individual nucleoside transporter genes are linked to various hematological abnormalities, including anemia. Here, we review recent developments in nucleoside transporters, including their transport characteristics, their role in the regulation of hematopoiesis, and their potential involvement in the occurrence of adverse hematological side effects due to nucleoside drug treatment. Furthermore, we discuss the putative mechanisms by which aberrant nucleoside transport may contribute to hematological abnormalities and identify the knowledge gaps where future research may positively impact treatment outcomes for patients undergoing various nucleoside analog therapies.

摘要

抗癌核苷类似物会产生不良的,有时甚至是剂量限制性的血液学毒性,这可能会影响治疗效果,然而,此类毒性的机制却知之甚少。最近,细胞核苷转运与正常血细胞生成有关,对核苷转运体缺陷小鼠的研究为哺乳动物造血的调控提供了更多见解。此外,几种特发性人类遗传疾病已表明核苷转运是哺乳动物造血的重要组成部分,因为单个核苷转运体基因的突变与各种血液学异常有关,包括贫血。在此,我们综述了核苷转运体的最新进展,包括它们的转运特性、在造血调控中的作用以及它们在核苷药物治疗引起的不良血液学副作用发生中的潜在作用。此外,我们讨论了异常核苷转运可能导致血液学异常的推定机制,并确定了知识空白,未来的研究可能会对接受各种核苷类似物治疗的患者的治疗结果产生积极影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aab4/9264962/77e02bb0951d/cancers-14-03113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aab4/9264962/eeb72718756c/cancers-14-03113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aab4/9264962/77e02bb0951d/cancers-14-03113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aab4/9264962/eeb72718756c/cancers-14-03113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aab4/9264962/77e02bb0951d/cancers-14-03113-g002.jpg

相似文献

1
Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective.造血作用和血液学药物毒性中的溶质载体核苷转运体:一种观点
Cancers (Basel). 2022 Jun 25;14(13):3113. doi: 10.3390/cancers14133113.
2
The role of transporters in the toxicity of nucleoside and nucleotide analogs.转运蛋白在核苷(酸)类似物毒性中的作用。
Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):665-76. doi: 10.1517/17425255.2012.680885. Epub 2012 Apr 18.
3
Identification of Structural and Molecular Features Involved in the Transport of 3'-Deoxy-Nucleoside Analogs by Human Equilibrative Nucleoside Transporter 3.鉴定与人嘧啶核苷转运蛋白 3 相关的 3'-脱氧核苷类似物转运的结构和分子特征。
Drug Metab Dispos. 2018 May;46(5):600-609. doi: 10.1124/dmd.117.079400. Epub 2018 Mar 12.
4
Mammalian nucleoside transporters.哺乳动物核苷转运体。
Curr Drug Metab. 2004 Feb;5(1):63-84. doi: 10.2174/1389200043489162.
5
The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs.核苷转运体在核苷类药物癌症化疗中的作用。
Cancer Metastasis Rev. 2007 Mar;26(1):85-110. doi: 10.1007/s10555-007-9044-4.
6
Stable expression of a recombinant sodium-dependent, pyrimidine-selective nucleoside transporter (CNT1) in a transport-deficient mouse leukemia cell line.重组钠依赖性嘧啶选择性核苷转运体(CNT1)在转运缺陷型小鼠白血病细胞系中的稳定表达。
Biochem Cell Biol. 1998;76(5):843-51. doi: 10.1139/bcb-76-5-843.
7
Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition.转运体转运核苷和结构类似药物:底物识别的结构要求。
Med Res Rev. 2012 Mar;32(2):428-57. doi: 10.1002/med.20221. Epub 2011 Feb 1.
8
Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity.核苷和核碱基转运蛋白基因表达与抗代谢药物细胞毒性的相关性。
J Exp Ther Oncol. 2002 Jul-Aug;2(4):200-12. doi: 10.1046/j.1359-4117.2002.01035.x.
9
A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: in vitro toxicity to precursor cells and microstromal environment.三种具有抗逆转录病毒活性的核苷类似物对小鼠免疫和造血功能的比较:对前体细胞和微基质环境的体外毒性
Toxicol Appl Pharmacol. 1989 Nov;101(2):328-39. doi: 10.1016/0041-008x(89)90281-0.
10
Transport of nucleoside analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity.核苷类似物跨质膜的转运:理解药物诱导细胞毒性的线索
Curr Drug Metab. 2009 May;10(4):347-58. doi: 10.2174/138920009788499030.

引用本文的文献

1
Acute therapy-related myelodysplastic syndromes following capecitabine and oxaliplatin therapy in gastric malignant tumor: A case report.卡培他滨和奥沙利铂治疗胃癌后出现的急性治疗相关性骨髓增生异常综合征:一例报告。
Medicine (Baltimore). 2024 Jul 26;103(30):e39049. doi: 10.1097/MD.0000000000039049.
2
Association between genetic variants of membrane transporters and the risk of high-grade hematologic adverse events in a cohort of Mexican children with B-cell acute lymphoblastic leukemia.墨西哥B细胞急性淋巴细胞白血病儿童队列中膜转运蛋白基因变异与高级别血液学不良事件风险的关联
Front Oncol. 2024 Jan 10;13:1276352. doi: 10.3389/fonc.2023.1276352. eCollection 2023.
3

本文引用的文献

1
Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions.克拉屈滨作为基于核苷转运体的药物相互作用的潜在对象。
Clin Pharmacokinet. 2022 Feb;61(2):167-187. doi: 10.1007/s40262-021-01089-9. Epub 2021 Dec 11.
2
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia.地西他滨单药治疗急性髓系白血病的临床价值。
Adv Ther. 2022 Apr;39(4):1474-1488. doi: 10.1007/s12325-021-01948-8. Epub 2021 Nov 16.
3
Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.口服阿扎胞苷(CC-486)治疗髓系恶性肿瘤。
Platinum-Nucleos(t)ide Compounds as Possible Antimetabolites for Antitumor/Antiviral Therapy: Properties and Perspectives.
铂-核苷(t)化合物作为抗肿瘤/抗病毒治疗的潜在抗代谢物:性质与前景
Pharmaceutics. 2023 Mar 14;15(3):941. doi: 10.3390/pharmaceutics15030941.
Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):236-250. doi: 10.1016/j.clml.2021.09.021. Epub 2021 Oct 8.
4
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.依尼西尼(enasidenib)联合阿扎胞苷对比阿扎胞苷单药治疗新诊断、突变型 IDH2 急性髓系白血病患者(AG221-AML-005):一项单臂、1b 期和随机、2 期试验。
Lancet Oncol. 2021 Nov;22(11):1597-1608. doi: 10.1016/S1470-2045(21)00494-0. Epub 2021 Oct 18.
5
Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis.地西他滨与阿扎胞苷治疗急性髓系白血病和高危骨髓增生异常综合征患者的比较:一项系统评价和网状Meta分析
Front Pharmacol. 2021 Aug 17;12:701690. doi: 10.3389/fphar.2021.701690. eCollection 2021.
6
NOTCH-mediated ex vivo expansion of human hematopoietic stem and progenitor cells by culture under hypoxia.NOTCH 通路介导的低氧培养下人造血干/祖细胞的体外扩增。
Stem Cell Reports. 2021 Sep 14;16(9):2336-2350. doi: 10.1016/j.stemcr.2021.08.001. Epub 2021 Aug 26.
7
Hormetic endoplasmic reticulum stress in hematopoietic stem cells.造血干细胞中的应激性内质网应激
Curr Opin Hematol. 2021 Nov 1;28(6):417-423. doi: 10.1097/MOH.0000000000000668.
8
Pluripotent and Multipotent Stem Cells and Current Therapeutic Applications: Review.多能和多潜能干细胞及其当前的治疗应用:综述
Stem Cells Cloning. 2021 Apr 12;14:3-7. doi: 10.2147/SCCAA.S304887. eCollection 2021.
9
Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status.T细胞和B细胞对克拉屈滨的不同敏感性取决于其与活化状态相关的脱氧胞苷激酶活性水平。
J Neuroimmune Pharmacol. 2022 Jun;17(1-2):195-205. doi: 10.1007/s11481-021-09994-3. Epub 2021 Apr 14.
10
Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.ADI-PEG20 联合小剂量阿糖胞苷治疗急性髓系白血病的 I 期研究。
Cancer Med. 2021 May;10(9):2946-2955. doi: 10.1002/cam4.3871. Epub 2021 Mar 30.